Shanghai Pharma gains Philippine approval for two injections

Shanghai Pharmaceuticals Holding received drug registration certificates from the Philippine Food and Drug Administration for oxytocin injection and octreotide acetate injection.

Each product had registration costs of approximately RMB 50,000 with no additional R&D costs. The approval grants the company rights to sell these medicines in the Philippine market.